Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNet

范德比尔特大学：临床中心申请，1 型糖尿病 TrialNet

• 批准号: 8913146
• 负责人: WILLIAM E RUSSELL
• 金额: $ 49.99万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8913146
• 关键词: Adult; Affect; Age; American; Area; Autoimmune Process; Back; Boston; Caring; Cells; Chicago; Child; Childhood; Clinic; Clinical; Clinical Trials; Collaborations; Communities; Development; Diabetes Mellitus; Diabetes prevention; Disease; Enrollment; Environment; Epidemiology; Family; Funding; Future; Future Generations; Genetic; Goals; Health; Health Care Costs; Immune system; Immunologics; Incidence; Individual; Institutional Review Boards; Insulin; Insulin-Dependent Diabetes Mellitus; International; Investments; Leadership; Life; Life Expectancy; Marketing; Metabolic; Mission; Monitor; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Outcome; Pancreas; Participant; Patients; Performance; Population; Positioning Attribute; Prevention; Prevention Research; Prevention strategy; Prevention trial; Process; Protocols documentation; Public Health; Public Relations; Radial; Recruitment Activity; Research; Research Personnel; Resources; Risk; Role; Site; Staging; Tennessee; Toddler; Training; Translational Research; United States National Institutes of Health; Universities; Work; base; career; clinical care; cost; diabetic patient; experience; improved; medical specialties; metropolitan; network models; novel; outreach; pediatric department; prevent; programs; screening; success; urban area

DESCRIPTION (provided by applicant): The incidence of Type 1 diabetes (T1D) has been increasing 3-5% per year for decades, most rapidly in the very young. A prevention strategy is essential to alleviate the tremendous personal and public health burden of diabetes and will likely also influence strategies to cure or reverse the disease in those already afflicted. As the only new Clinical Center admitted to the TrialNet consortium in 2009, Vanderbilt University has an extremely strong record of participant recruitment and engagement and is well-positioned among Clinical Centers to continue to make a difference in the success of TrialNet. Our center brings abundant resources for the work proposed. We have a very large and carefully followed T1D patient and family base from which to continue to draw participants. We have gained substantial community involvement and endorsement of our efforts and have a very strong record of participant engagement and retention in clinical trials, currently being the leading recruitment site for the two ongoing prevention trials that were initiated since our entry. We have developed a widely distributed and enthusiastic group of 14 Affiliates, well supported by our Center, to bring TrialNet to a broad spectrum of small communities and metropolitan areas throughout the US. Our experience will allow us to take advantage of opportunities to add new affiliates and expand and enhance the activities of underperforming affiliates. We propose novel directions to further our reach: an extension of our Center's presence to multiple autoimmune patient communities at the local and national levels, a hitherto underutilized reservoir of T1D families eligible for screening. We have developed a partnership with the Tennessee Department of Health to bring TrialNet into all public health centers of the state of Tennessee, which if successful, could be a network model for outreach in other states. The media outreach of our center has been extensive and we propose an expanded national and international media presence that will continue to benefit the entire network. We document the leadership roles that our PI and coordinators have had at the network level in the development and execution of new prevention studies, in public relations, in affiliate management and engagement, and in study coordination. We document strong institutional support of our application by both the Vanderbilt Diabetes Center and the Department of Pediatrics in ways that amplify the financial investment by the NIDDK. Vanderbilt University will support any options the network endorses to expedite IRB approval of studies. Finally, we demonstrate a strong pool of early stage investigators whose careers have already been influenced by TrialNet at Vanderbilt. We outline a plan to more vigorously engage them intellectually and scientifically in the work of the network while furthering their careers. Using this broad and diverse set of TrialNet-inspired resources, the TrialNet Clinical Center at Vanderbilt is well positioned to be a leader in T1D prevention and in improving the lives of people with T1D throughout the world.

描述（由申请人提供）：数十年来，1型糖尿病（T1D）的发病率一直在每年增加3-5％，最年轻。一种预防策略对于减轻糖尿病的巨大个人和公共卫生负担至关重要，并且可能还会影响已经遭受折磨的人治愈或扭转这种疾病的策略。范德比尔特大学（Vanderbilt University）是2009年唯一进入试验网联盟的新临床中心，在参与者招募和参与度方面具有极强的记录，并且在临床中心中置于良好的位置，以继续在试验网的成功方面有所作为。我们的中心为提议的工作带来了丰富的资源。我们有一个非常大的仔细跟随T1D患者和家庭基础，可以继续吸引参与者。我们已经获得了社区的大量参与和认可，并且在临床试验中的参与和保留率很强，目前是自我们进入以来开始的两个正在进行的预防试验的领先招聘地点。我们有 由我们中心提供了广泛的14个分支机构，开发了一个广泛的分布和热情的小组，以将试验网络带到美国各地的各种小社区和大都市地区。我们的经验将使我们能够利用机会增加新的分支机构，扩大和增强表现不佳的分支机构的活动。我们提出了新的方向以进一步发展：将中心的存在扩展到本地和国家一级的多个自身免疫性患者社区，这是迄今未充分利用的T1D家族的水库，有资格进行筛查。我们已经与田纳西州卫生部建立了合作伙伴关系，以将试验网络带入田纳西州所有公共卫生中心，如果成功，这可能是其他州外展的网络模型。媒体对我们中心的宣传非常广泛，我们提出了扩大的国家和国际媒体影响力，将继续受益于整个网络。我们记录了我们的PI和协调员在新的预防研究，公共关系，会员管理和参与以及研究协调方面的领导力角色。我们以范德比尔特糖尿病中心和儿科部对我们的申请进行了强有力的机构支持，以扩大NIDDK的金融投资的方式。范德比尔特大学（Vanderbilt University）将支持网络认可以加快IRB批准研究的任何选择。最后，我们展示了大量的早期调查人员，他们的职业已经受到范德比尔特（Vanderbilt）试验网的影响。我们概述了一项计划，以在促进其职业生涯的同时，在网络的工作中更加有力地参与他们的智力和科学参与。范德比尔特（Vanderbilt）的试验网临床中心使用这套广泛而多样化的试验网络启发的资源，可以成为预防T1D的领导者，并改善了全世界T1D的人的生活。